

ACURA PHARMACEUTICALS, INC  
Form 8-K  
September 09, 2015

UNITED STATES

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D. C. 20549**

---

FORM 8-K

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act Of 1934**

**September 9, 2015**

Date of Report (Date of earliest event reported)

---

**ACURA PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in Charter)

---

State of New York (State of Other Jurisdiction of Incorporation)	1-10113 (Commission File Number)	11-0853640 (I.R.S. Employer Identification Number)
--	-------------------------------------	--

616 N. North Court, Suite 120

Palatine, Illinois 60067

Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 8-K

(Address of principal executive offices) (Zip Code)

**(847) 705-7709**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-J(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-L(c))

**Item 8.01 Other Events**

On September 9, 2015 we issued a press release disclosing the commercial launch of Oxaydo™ (oxycodone HCl) tablets in the United States by our licensing partner, Egalet Corporation. A copy of our press release is attached as Exhibit 99.1 hereto.

**Item 9.01 Financial Statements and Exhibits**

<b><u>Exhibit Number</u></b>	<b><u>Description</u></b>
99.1	Press Release dated September 9, 2015 announcing the commercial launch of Oxaydo™ (oxycodone HCl) tablets in the United States by our licensing partner, Egalet Corporation.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**ACURA  
PHARMACEUTICALS,  
INC.**

By: /s/ Peter A. Clemens  
Peter A. Clemens  
Senior Vice President  
& Chief Financial  
Officer

Date: September 9, 2015

**Exhibit Index**

<b><u>Exhibit Number</u></b>	<b><u>Description</u></b>
99.1	Press Release dated September 9, 2015 announcing the commercial launch of Oxaydo™ (oxycodone HCl) tablets in the United States by our licensing partner, Egalet Corporation.